AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35896943
Drug: Viloxazine ER
RxNorm normalized name: viloxazine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viloxazine ER (200–600 mg/day)
Trial: 32172522
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (one‐time oral dose of 120,000 IU)
Trial: 32172522
Drug: Placebo (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (8 mg of saccharide)
Trial: 33992280
Drug: IASTM +
RxNorm normalized name: MASK,SURGICAL RECTANGULAR ASTM LEVEL 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IASTM + conventional treatment
Trial: 35975719
Drug: Autologous Blood
RxNorm normalized name: Banked autologous blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous Blood Injection (ABI)
Trial: 32601710
Drug: Intermittent Theta
RxNorm normalized name: Coptis teeta root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent Theta Burst Stimulation (iTBS) - 20 bilateral treatments (1 session per day, 5 days per week over a 4-week period)
Trial: 34496450
Drug: Garlic supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garlic supplementation (800 mg/day)
Trial: 34151413
Drug: Doravirine 100
RxNorm normalized name: doravirine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doravirine 100 mg QD for 5 days
Trial: 34151413
Drug: Islatravir 2.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Islatravir 2.25 mg QD for 14 days
Trial: 34151413
Drug: Coadministration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coadministration of islatravir 2.25 mg and doravirine 100 mg QD for 5 days
Trial: 33283731
Drug: Decitabine combined
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine combined with low-dose CEG regimen (DCEG)
Trial: 33283731
Drug: Decitabine combined
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine combined with low-dose CAG regimen (DCAG)
Trial: 33283731
Drug: Decitabine combined
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine combined with low-dose CEG regimen (DCEG) and Decitabine combined with low-dose CAG regimen (DCAG)
Trial: 34261600
Drug: Ghamz therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ghamz therapy
Trial: 33852758
Drug: Gelato APF
RxNorm normalized name: Gelato APF 1.81 % Dental Foam
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gelato APF Gel
Trial: 33284677
Drug: 1000 IU/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 IU/d or higher doses of vitamin D3
Trial: 33284677
Drug: Experience-with-best-dose group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experience-with-best-dose group (1000 IU/d)
Trial: 32135126
Drug: Mifepristone 200
RxNorm normalized name: mifepristone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 200 mg followed by misoprostol 200 mcg buccally
Trial: 32135126
Drug: Placebo followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo followed by misoprostol 200 mcg buccally
Trial: 35763247
Drug: Upacicalcet (0.025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upacicalcet (0.025 to 0.8 mg single-dose)
Trial: 35763247
Drug: Upacicalcet (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upacicalcet (0.05 to 0.2 mg multiple-dose)
Trial: 35333783
Drug: Targeted albumin
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted albumin infusions
Trial: 32307430
Drug: Cytoflavin (intravenously,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoflavin (intravenously, drip 20.0 ml in 250.0 ml 5% glucose for 14 days)
Trial: 36226798
Drug: Medication reminder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication reminder app
Trial: 34346168
Drug: 70 mg
RxNorm normalized name: silybin 70 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 mg astegolimab every 4 weeks
Trial: 34346168
Drug: 210 mg
RxNorm normalized name: aspirin 210 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 210 mg astegolimab every 4 weeks
Trial: 34346168
Drug: 490 mg
RxNorm normalized name: thimerosal 490 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 490 mg astegolimab every 4 weeks
Trial: 33736675
Drug: Eribulin mesylate
RxNorm normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eribulin mesylate (0.82 mg/m2/week in group A to 0.65 mg/m2/week in group D)
Trial: 33444970
Drug: Almond consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almond consumption (2 servings, 56 g/day)
Trial: 36495483
Drug: Oral ulipristal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ulipristal acetate regimens
Trial: 33568086
Drug: Cochlear implants
RxNorm normalized name: Cochlearia officinalis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cochlear implants (CI) in children aged 4-6 years
Trial: 33568086
Drug: Cochlear implants
RxNorm normalized name: Cochlearia officinalis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cochlear implants (CI) in children aged 7-9 years
Trial: 32541143
Drug: Temsirolimus (TEM)
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Temsirolimus (TEM) 25 mg i.v. once a week
Trial: 32541143
Drug: Sunitinib (SUN)
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sunitinib (SUN) 50 mg p.o. daily for 4 weeks on and 2 weeks off
Trial: 36375173
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg duloxetine
Trial: 34082620
Drug: Anemia treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anemia treatment (iron, erythropoiesis-stimulating agents, and/or red blood cell transfusion)
Trial: 34082620
Drug: No anemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No anemia treatment
Trial: 33103322
Drug: Novel treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel treatments
Trial: 36920778
Drug: Placebo (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (administered subcutaneously every 2 weeks)
Trial: 33440077
Drug: Letermovir (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letermovir (oral and intravenous administration)
Trial: 35362109
Drug: QFR-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QFR-based treatment recommendations
Trial: 35362109
Drug: FFR-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FFR-based treatment recommendations
Trial: 33296982
Drug: Salbutamol 2
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol 2 mg twice a day
Trial: 34302758
Drug: Itepekimab 300
RxNorm normalized name: Itepekimab
DrugBank: Itepekimab (DB16206)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itepekimab 300 mg administered as two subcutaneous injections every 2 weeks for 24-52 weeks
Trial: 35430997
Drug: Ibuprofen/Caffeine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen/Caffeine combination (400/100 mg)
Trial: 33504513
Drug: Double-dose clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-dose clopidogrel (600 mg, day 1; 150 mg, days 2-7; then 75 mg/day)
Trial: 33504513
Drug: Standard-dose clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose clopidogrel (300 mg, day 1; then 75 mg/day)
Trial: 34302129
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g l-arginine and 1.2 g aged garlic extract (AGE) daily for 6 weeks
Trial: 33496884
Drug: Basal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal diet supplemented with Zn-Met 60 mg/kg (T3)
Trial: 33496884
Drug: Basal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal diet supplemented with Zn-Met 40 mg/kg (T2)
Trial: 33496884
Drug: Basal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal diet supplemented with Zn-Met 20 mg/kg (T1)
Trial: 33496884
Drug: Basal diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal diet (control, 40 mg/kg)
Trial: 32323557
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D treatment (150,000 IU daily for 3 days before surgery)
Trial: 34590235
Drug: Office-based extended-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Office-based extended-release naltrexone
Trial: 36453001
Drug: Narrative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrative therapy group sessions (8 weekly 2-hour sessions)
Trial: 35948454
Drug: Strength training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strength training plus proprioceptive neuromuscular facilitation (PNF) therapy
Trial: 34683948
Drug: GF:IF =
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GF:IF = 0.5 with cumulative dose of 1.5 mg salbutamol
Trial: 34683948
Drug: GF:IF =
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GF:IF = 1.0 with cumulative dose of 1.5 mg salbutamol
Trial: 34683948
Drug: GF =
RxNorm normalized name: Glatiramer Acetate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GF = 50 L/min with cumulative dose of 1.5 mg salbutamol
Trial: 34683948
Drug: GF:IF =
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GF:IF = 0.5 with cumulative dose of 3.5 mg salbutamol
Trial: 34683948
Drug: GF:IF =
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GF:IF = 1.0 with cumulative dose of 3.5 mg salbutamol
Trial: 34683948
Drug: GF =
RxNorm normalized name: Glatiramer Acetate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GF = 50 L/min with cumulative dose of 3.5 mg salbutamol
Trial: 35794674
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine at a rate of 1 mg/h for the first 6 hours postoperatively, with adjustments based on NRS pain evaluation
Trial: 35794674
Drug: Intravenous acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous acetaminophen 1 g every 6 hours and ketorolac 30 mg every 8 hours for the first 3 postoperative days
Trial: 33386290
Drug: Optimal local
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal local treatment for nodal oligorecurrent prostate cancer
Trial: 35842821
Drug: Compound microporous
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound microporous polysaccharide hemostatic powder (CMPHP)
Trial: 32229495
Drug: Contezolid (MRX-I)
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contezolid (MRX-I) therapeutic dose (800 mg)
Trial: 32229495
Drug: Contezolid (MRX-I)
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contezolid (MRX-I) supratherapeutic dose (1,600 mg)
Trial: 32507624
Drug: Beetroot juice
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beetroot juice (BJ) supplementation (140 mL nitrate-rich BJ concentrate)
Trial: 36044708
Drug: Carbohydrate (CHO:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate (CHO: 1 g/kg/h)
Trial: 33705205
Drug: Adavosertib monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adavosertib monotherapy (300 mg orally once daily on days 1-5 and 8-12 of a 21-day cycle)
Trial: 36469840
Drug: Adavosertib monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adavosertib monotherapy
Trial: 32075958
Drug: Oral cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cannabis (6.9% THC, 50.6 mg)
Trial: 32075958
Drug: Smoked cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoked cannabis (6.9% THC, 50.6 mg)
Trial: 32075958
Drug: Vaporized cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaporized cannabis (6.9% THC, 50.6 mg)
Trial: 34162404
Drug: Standard intensive
RxNorm normalized name: MACADAMIA OIL 2 g in 100 g / CERAMIDE NP 0.0006 g in 100 g / PANTHENOL 0.75 g in 100 g / CENTELLA ASIATICA WHOLE 0.003 g in 100 g TOPICAL CREAM [ATO STANDARD INTENSIVECREAM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intensive chemotherapy
Trial: 32216555
Drug: Colistin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colistin (20 mg/kg)
Trial: 32216555
Drug: Tylosin (55
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tylosin (55 mg/kg)
Trial: 32216555
Drug: Chlortetracycline (CTC,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlortetracycline (CTC, 55 mg/kg)
Trial: 35641878
Drug: IV lignocaine
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV lignocaine infusion (1.5 mg/kg at induction followed by 1.5 mg/kg/h for 1 hour in PACU)
Trial: 35641878
Drug: IV lignocaine
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV lignocaine infusion
Trial: 35641878
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline IV infusion
Trial: 35465764
Drug: Acknowledgment of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acknowledgment of vaccine hesitancy
Trial: 33125753
Drug: SAR247799 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAR247799 1 mg
Trial: 33125753
Drug: SAR247799 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAR247799 5 mg
Trial: 33125753
Drug: Sildenafil 50
RxNorm normalized name: sildenafil 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 50 mg (positive control)
Trial: 33257343
Drug: Hyoscine butylbromide
RxNorm normalized name: Hyoscine butylbromide
DrugBank: Butylscopolamine (DB09300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscine butylbromide (10 mg orally)
Trial: 33257343
Drug: Acetaminophen (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (15 mg/kg orally, max 975 mg)
Trial: 33244719
Drug: Laparoscopic surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic surgery for rectal cancer
Trial: 34020931
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy (ADT) plus docetaxel (75 mg/m2 q3w for ten cycles)
Trial: 32313142
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy (ADT) plus docetaxel
Trial: 32392455
Drug: Lurasidone 20-80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone 20-80 mg
Trial: 95358022
Drug: S +
RxNorm normalized name: K-Y Yours + Mine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S + preS2 vaccine
Trial: 95358022
Drug: S vaccine
RxNorm normalized name: Mumps vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S vaccine
Trial: 95358022
Drug: Any vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any vaccine used
Trial: 34889883
Drug: Injection Cerebrolysin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection Cerebrolysin 5 mL diluted in 100 mL Normal Saline over 30 minutes once a day for 21 days postoperatively
Trial: 33883195
Drug: Basal-bolus insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal-bolus insulin (BBI) regimen
Trial: 33883195
Drug: Fixed ratio
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed ratio of basal insulin plus GLP-1RA (fixed-combo group)
Trial: 33883195
Drug: Basal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal insulin plus SGLT2 inhibitor (gliflo-combo group)
Trial: 33734144
Drug: Intravenous Opioid
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Opioid Analgesia (PCA-M)
Trial: 32037263
Drug: 12-week hospital
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week hospital based physical therapy (intervention group, n=8)
Trial: 32453406
Drug: Withdrawal plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal plus preventive treatment
Trial: 32453406
Drug: Preventive treatment
RxNorm normalized name: STANNOUS FLUORIDE 0.004 g in 1 g DENTAL GEL [Enamelon Preventive Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive treatment without withdrawal
Trial: 32453406
Drug: Withdrawal with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Withdrawal with optional preventive treatment 2 months after withdrawal
Trial: 36942420
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of exercise and liraglutide 3.0 mg/d
Trial: 38227621
Drug: Liraglutide 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 3.0 mg/d
Trial: 32342247
Drug: Perioperative GL
RxNorm normalized name: GL-2045
DrugBank: GL-2045 (DB16971)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative GL group receiving 100 mL of 5% glucose solution immediately after local anesthesia
Trial: 32342247
Drug: Postoperative GL
RxNorm normalized name: GL-2045
DrugBank: GL-2045 (DB16971)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative GL group receiving 100 mL of 5% glucose solution immediately after surgery completion
Trial: 32342247
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving glucose-free sodium lactate Ringer's solution
Trial: 34080920
Drug: Mirtazapine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine (15 mg at bedtime)
Trial: 35775129
Drug: Simultaneous integrated
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous integrated boost (SIB) protocol with 4.45 Gy dose increase
Trial: 33541062
Drug: Pendulum treatment
RxNorm normalized name: Aconitum pendulum root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pendulum treatment for molar distalization over 6 months
Trial: 33541062
Drug: Pendulum treatment
RxNorm normalized name: Aconitum pendulum root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pendulum treatment for molar distalization
Trial: 33541062
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment) after one year
Trial: 32865062
Drug: Chemotherapy perfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy perfusion
Trial: 32396592
Drug: Cranberry juice
RxNorm normalized name: cranberry juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry juice drink (375 mg total flavan‐3‐ols)
Trial: 32396592
Drug: Cranberry juice
RxNorm normalized name: cranberry juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry juice drink (716 mg total flavan‐3‐ols)
Trial: 32396592
Drug: Cranberry juice
RxNorm normalized name: cranberry juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry juice drink (1131 mg total flavan‐3‐ols)
Trial: 32396592
Drug: Cranberry juice
RxNorm normalized name: cranberry juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry juice drink (1396 mg total flavan‐3‐ols)
Trial: 32396592
Drug: Cranberry juice
RxNorm normalized name: cranberry juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry juice drink (1741 mg total flavan‐3‐ols)
Trial: 32378071
Drug: Modified FOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified FOLFOX6 (oxaliplatin in combination with 5‐fluorouracil and l‐leucovorin)
Trial: 33415858
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group (Escitalopram Oxalate tablets 5-20 mg/d)
Trial: 34836079
Drug: EXCO (exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EXCO (exercise + 2 g/day oil from Calanus finmarchicus)
Trial: 34836079
Drug: CON (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CON (control group, no treatment)
Trial: 34102553
Drug: Phone-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phone-based intervention under nurse guidance including home BP monitoring, medication reminders, and education on hypertension delivered weekly for 12 months.
Trial: 35217670
Drug: albendazole and
RxNorm normalized name: Albendazole and ivermectin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: albendazole and ivermectin combination therapy
Trial: 36944461
Drug: Taurolidine-citrate-heparin lock
RxNorm normalized name: heparin / taurolidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taurolidine-citrate-heparin lock solution
Trial: 34903116
Drug: Fluoridated milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoridated milk (F-milk) adjunctive to 1000-ppm fluoride dentifrice (FD)